NERM
IONS icon

New England Research & Management’s Ionis Pharmaceuticals IONS Stock Holding History

New England Research & Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,890
Closed -$1.11M – 146
2020
Q2 		$1.11M Sell
18,890
-1,150
-6% -$64K 0.8% 42
2020
Q1 		$947K Buy
20,040
+10,490
+110% +$585K 0.81% 41
2019
Q4 		$577K Buy
+9,550
New +$569K 0.39% 88

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

New England Research & Management's IONS Position: Q3 2020 in Review

New England Research & Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 18,890 shares — an estimated $1.11M sold.

New England Research & Management first reported a position in IONS in Q4 2019 and held it in 3 quarters. The position peaked at $1.11M in Q2 2020. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • New England Research & Management reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • New England Research & Management sold 18,890 Ionis Pharmaceuticals shares in Q3 2020, an estimated $1.11M.
  • New England Research & Management first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • New England Research & Management's Ionis Pharmaceuticals position peaked at $1.11M in Q2 2020.
  • 367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on New England Research & Management's 13F filing for Q3 2020, filed 8 Oct 2020.